[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fHVEPyYmloIkPTwE4O7Hqb0kudTp1pHKko57fldkwe1Q":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":55,"rows":62},"Atlantic Health System",[4],61,false,9,0,8024,4,46,[14,17,19,22,25,27,29,32],{"name":15,"count":16},"Pelvic Organ Prolapse",11,{"name":18,"count":11},"Urinary Incontinence",{"name":20,"count":21},"Vaginal Discharge",3,{"name":23,"count":24},"Stress Urinary Incontinence",2,{"name":26,"count":24},"Mesh Erosion",{"name":28,"count":24},"Mitral Regurgitation",{"name":30,"count":31},"Vaginal Prolapse",1,{"name":33,"count":31},"Pancreatic Cancer",[35,40,45,50],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT05519072","Use of Prophylactic Antibiotics Prior to OnabotulinumtoxinA","2024-08-16","Nitrofurantoin",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT06961604","A Novel Method for Determination of Thromboembolic Stroke Origin","2025-06-01","NaF PET-CT",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT06810687","Is Methenamine Prophylaxis for Urinary Tract Infection After Midurethral Sling as Effective as Antibiotic Prophylaxis?","2027-07-30","Methenamine Hippurate 1g BD",{"nctId":51,"briefTitle":52,"date":53,"intervention":54},"NCT07614321","Silodosin for Urinary Symptoms in Female Patients With Multiple Sclerosis","2028-03","Silodosin 8 mg",[56,57,58,59,60,61],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[63,85,108,130,152,179,206,224,249,277,295,326,344,368,386,412,447,472,497],{"intervention":39,"totalTrials":31,"cells":64},{"EARLY_PHASE1":65,"PHASE1":67,"PHASE2":69,"PHASE3":71,"PHASE4":73,"NA":83},{"trials":66,"activeCount":9},[],{"trials":68,"activeCount":9},[],{"trials":70,"activeCount":9},[],{"trials":72,"activeCount":9},[],{"trials":74,"activeCount":31,"soonestReadout":38},[75],{"nctId":36,"briefTitle":37,"status":76,"phases":77,"primaryCompletion":38,"completion":38,"start":78,"enrollment":79,"conditions":80,"interventions":82},"RECRUITING",[60],"2022-08-16",140,[81],"Antibiotic Prophylaxis",[39],{"trials":84,"activeCount":9},[],{"intervention":54,"totalTrials":31,"cells":86},{"EARLY_PHASE1":87,"PHASE1":89,"PHASE2":91,"PHASE3":93,"PHASE4":95,"NA":106},{"trials":88,"activeCount":9},[],{"trials":90,"activeCount":9},[],{"trials":92,"activeCount":9},[],{"trials":94,"activeCount":9},[],{"trials":96,"activeCount":31,"soonestReadout":53},[97],{"nctId":51,"briefTitle":52,"status":76,"phases":98,"primaryCompletion":53,"completion":99,"start":100,"enrollment":101,"conditions":102,"interventions":105},[60],"2028-04","2026-04",60,[103,104],"Multiple Sclerosis","Lower Urinary Track Symptoms",[54],{"trials":107,"activeCount":9},[],{"intervention":44,"totalTrials":31,"cells":109},{"EARLY_PHASE1":110,"PHASE1":120,"PHASE2":122,"PHASE3":124,"PHASE4":126,"NA":128},{"trials":111,"activeCount":31,"soonestReadout":43},[112],{"nctId":41,"briefTitle":42,"status":113,"phases":114,"primaryCompletion":43,"completion":115,"start":43,"enrollment":116,"conditions":117,"interventions":119},"NOT_YET_RECRUITING",[56],"2026-05-31",20,[118],"Thromboembolic Stroke",[44],{"trials":121,"activeCount":9},[],{"trials":123,"activeCount":9},[],{"trials":125,"activeCount":9},[],{"trials":127,"activeCount":9},[],{"trials":129,"activeCount":9},[],{"intervention":49,"totalTrials":31,"cells":131},{"EARLY_PHASE1":132,"PHASE1":134,"PHASE2":136,"PHASE3":138,"PHASE4":140,"NA":142},{"trials":133,"activeCount":9},[],{"trials":135,"activeCount":9},[],{"trials":137,"activeCount":9},[],{"trials":139,"activeCount":9},[],{"trials":141,"activeCount":9},[],{"trials":143,"activeCount":31,"soonestReadout":48},[144],{"nctId":46,"briefTitle":47,"status":76,"phases":145,"primaryCompletion":48,"completion":146,"start":147,"enrollment":148,"conditions":149,"interventions":151},[61],"2028-01-30","2025-01-30",190,[150],"Urinary Tract Infection (Diagnosis)",[49],{"intervention":153,"totalTrials":31,"cells":154},"Lidocaine gel 2%",{"EARLY_PHASE1":155,"PHASE1":157,"PHASE2":159,"PHASE3":161,"PHASE4":163,"NA":177},{"trials":156,"activeCount":9},[],{"trials":158,"activeCount":9},[],{"trials":160,"activeCount":9},[],{"trials":162,"activeCount":9},[],{"trials":164,"activeCount":9},[165],{"nctId":166,"briefTitle":167,"status":168,"phases":169,"primaryCompletion":170,"completion":170,"start":171,"enrollment":172,"conditions":173,"interventions":176},"NCT03390790","Lidocaine for Pain After Urodynamic Testing","COMPLETED",[60],"2019-03-29","2018-01-25",134,[174,175,18],"Voiding Disorders","Overactive Bladder",[153],{"trials":178,"activeCount":9},[],{"intervention":180,"totalTrials":31,"cells":181},"Intravesical antibiotic instillation",{"EARLY_PHASE1":182,"PHASE1":184,"PHASE2":186,"PHASE3":188,"PHASE4":190,"NA":204},{"trials":183,"activeCount":9},[],{"trials":185,"activeCount":9},[],{"trials":187,"activeCount":9},[],{"trials":189,"activeCount":9},[],{"trials":191,"activeCount":9},[192],{"nctId":193,"briefTitle":194,"status":195,"phases":196,"primaryCompletion":197,"completion":197,"start":198,"enrollment":199,"conditions":200,"interventions":202},"NCT04285320","Antibiotic Bladder Instillations vs. Oral Suppression for the Treatment of Recurrent Urinary Tract Infections","UNKNOWN",[60],"2023-04","2021-03",100,[201],"Recurrent Urinary Tract Infection",[180,203],"Antibiotic oral suppressive therapy",{"trials":205,"activeCount":9},[],{"intervention":203,"totalTrials":31,"cells":207},{"EARLY_PHASE1":208,"PHASE1":210,"PHASE2":212,"PHASE3":214,"PHASE4":216,"NA":222},{"trials":209,"activeCount":9},[],{"trials":211,"activeCount":9},[],{"trials":213,"activeCount":9},[],{"trials":215,"activeCount":9},[],{"trials":217,"activeCount":9},[218],{"nctId":193,"briefTitle":194,"status":195,"phases":219,"primaryCompletion":197,"completion":197,"start":198,"enrollment":199,"conditions":220,"interventions":221},[60],[201],[180,203],{"trials":223,"activeCount":9},[],{"intervention":225,"totalTrials":31,"cells":226},"Weekly wound spray with components 1 and 2 of the compound HP802-247",{"EARLY_PHASE1":227,"PHASE1":229,"PHASE2":231,"PHASE3":243,"PHASE4":245,"NA":247},{"trials":228,"activeCount":9},[],{"trials":230,"activeCount":9},[],{"trials":232,"activeCount":9},[233],{"nctId":234,"briefTitle":235,"status":195,"phases":236,"primaryCompletion":237,"completion":237,"start":238,"enrollment":239,"conditions":240,"interventions":242},"NCT01320605","Trial of Compassionate Use of hp802-247 to Treat Venous Leg Ulcers in Subjects Who Have Failed Multiple Other Healing Technologies",[58],"2012-06","2011-03",5,[241],"Venous Leg Ulcer",[225],{"trials":244,"activeCount":9},[],{"trials":246,"activeCount":9},[],{"trials":248,"activeCount":9},[],{"intervention":250,"totalTrials":31,"cells":251},"Exparel Injectable Product",{"EARLY_PHASE1":252,"PHASE1":254,"PHASE2":256,"PHASE3":271,"PHASE4":273,"NA":275},{"trials":253,"activeCount":9},[],{"trials":255,"activeCount":9},[],{"trials":257,"activeCount":9},[258],{"nctId":259,"briefTitle":260,"status":261,"phases":262,"primaryCompletion":263,"completion":263,"start":264,"enrollment":265,"conditions":266,"interventions":269},"NCT05355597","\"The Efficacy of Exparel Versus a Multidrug Cocktail in Soft Tissue Tumors\"","TERMINATED",[58],"2025-03-24","2021-01-27",116,[267,268],"Musculoskeletal Diseases","Soft Tissue Mass",[250,270],"Multi-Drug Cocktail",{"trials":272,"activeCount":9},[],{"trials":274,"activeCount":9},[],{"trials":276,"activeCount":9},[],{"intervention":270,"totalTrials":31,"cells":278},{"EARLY_PHASE1":279,"PHASE1":281,"PHASE2":283,"PHASE3":289,"PHASE4":291,"NA":293},{"trials":280,"activeCount":9},[],{"trials":282,"activeCount":9},[],{"trials":284,"activeCount":9},[285],{"nctId":259,"briefTitle":260,"status":261,"phases":286,"primaryCompletion":263,"completion":263,"start":264,"enrollment":265,"conditions":287,"interventions":288},[58],[267,268],[250,270],{"trials":290,"activeCount":9},[],{"trials":292,"activeCount":9},[],{"trials":294,"activeCount":9},[],{"intervention":296,"totalTrials":31,"cells":297},"Erythropoietin",{"EARLY_PHASE1":298,"PHASE1":300,"PHASE2":302,"PHASE3":320,"PHASE4":322,"NA":324},{"trials":299,"activeCount":9},[],{"trials":301,"activeCount":9},[],{"trials":303,"activeCount":9},[304],{"nctId":305,"briefTitle":306,"status":261,"phases":307,"primaryCompletion":308,"completion":308,"start":309,"enrollment":310,"conditions":311,"interventions":318},"NCT00589953","High-Dose Erythropoietin in Extremely Premature Infants to Prevent\u002FAttenuate Brain Injury: A Phase II Study",[58],"2010-09","2007-07",22,[312,296,313,314,315,316,317],"Infant, Premature","Brain Injury","Intraventricular Hemorrhage","Periventricular Leukomalacia","Neurodevelopmental Outcomes","Randomized Clinical Trial",[296,319],"Saline placebo",{"trials":321,"activeCount":9},[],{"trials":323,"activeCount":9},[],{"trials":325,"activeCount":9},[],{"intervention":319,"totalTrials":31,"cells":327},{"EARLY_PHASE1":328,"PHASE1":330,"PHASE2":332,"PHASE3":338,"PHASE4":340,"NA":342},{"trials":329,"activeCount":9},[],{"trials":331,"activeCount":9},[],{"trials":333,"activeCount":9},[334],{"nctId":305,"briefTitle":306,"status":261,"phases":335,"primaryCompletion":308,"completion":308,"start":309,"enrollment":310,"conditions":336,"interventions":337},[58],[312,296,313,314,315,316,317],[296,319],{"trials":339,"activeCount":9},[],{"trials":341,"activeCount":9},[],{"trials":343,"activeCount":9},[],{"intervention":345,"totalTrials":31,"cells":346},"carboplatin",{"EARLY_PHASE1":347,"PHASE1":349,"PHASE2":351,"PHASE3":362,"PHASE4":364,"NA":366},{"trials":348,"activeCount":9},[],{"trials":350,"activeCount":9},[],{"trials":352,"activeCount":9},[353],{"nctId":354,"briefTitle":355,"status":195,"phases":356,"start":357,"conditions":358,"interventions":360},"NCT00014105","Combination Chemotherapy in Treating Patients With Recurrent Glioblastoma Multiforme",[57,58],"2000-12",[359],"Brain and Central Nervous System Tumors",[345,361],"temozolomide",{"trials":363,"activeCount":9},[],{"trials":365,"activeCount":9},[],{"trials":367,"activeCount":9},[],{"intervention":361,"totalTrials":31,"cells":369},{"EARLY_PHASE1":370,"PHASE1":372,"PHASE2":374,"PHASE3":380,"PHASE4":382,"NA":384},{"trials":371,"activeCount":9},[],{"trials":373,"activeCount":9},[],{"trials":375,"activeCount":9},[376],{"nctId":354,"briefTitle":355,"status":195,"phases":377,"start":357,"conditions":378,"interventions":379},[57,58],[359],[345,361],{"trials":381,"activeCount":9},[],{"trials":383,"activeCount":9},[],{"trials":385,"activeCount":9},[],{"intervention":387,"totalTrials":31,"cells":388},"CPI 613 in Combination With Gemcitabine and Nab-paclitaxel",{"EARLY_PHASE1":389,"PHASE1":391,"PHASE2":404,"PHASE3":406,"PHASE4":408,"NA":410},{"trials":390,"activeCount":9},[],{"trials":392,"activeCount":9},[393],{"nctId":394,"briefTitle":395,"status":195,"phases":396,"primaryCompletion":397,"completion":398,"start":399,"enrollment":400,"conditions":401,"interventions":403},"NCT03435289","A Study of CPI-613 With Gemcitabine and Nab-paclitaxel for Patients With Advanced or Metastatic Pancreatic Cancer",[57],"2018-11","2019-01","2017-10-19",24,[33,402],"Metastatic Pancreatic Cancer",[387],{"trials":405,"activeCount":9},[],{"trials":407,"activeCount":9},[],{"trials":409,"activeCount":9},[],{"trials":411,"activeCount":9},[],{"intervention":413,"totalTrials":24,"cells":414},"Liposomal Bupivacaine",{"EARLY_PHASE1":415,"PHASE1":417,"PHASE2":419,"PHASE3":421,"PHASE4":423,"NA":434},{"trials":416,"activeCount":9},[],{"trials":418,"activeCount":9},[],{"trials":420,"activeCount":9},[],{"trials":422,"activeCount":9},[],{"trials":424,"activeCount":9},[425],{"nctId":426,"briefTitle":427,"status":195,"phases":428,"primaryCompletion":429,"completion":429,"start":430,"enrollment":431,"conditions":432,"interventions":433},"NCT03664986","Pudendal Block Using Liposomal Bupivacaine vs. Standard Treatment During Sacrospinous Ligament Fixation",[60],"2021-12-01","2018-09-24",88,[30],[413],{"trials":435,"activeCount":9},[436],{"nctId":437,"briefTitle":438,"status":168,"phases":439,"primaryCompletion":440,"completion":440,"start":441,"enrollment":442,"conditions":443,"interventions":445},"NCT02875015","Liposomal Bupivacaine vs. Bupivacaine Hydrochloride and Lidocaine During Suburethral Sling Placement",[61],"2018-05","2016-04",57,[444],"Postoperative Pain",[413,446],"Bupivacaine Hydrochloride and Lidocaine",{"intervention":448,"totalTrials":31,"cells":449},"Lidocaine patch 5%",{"EARLY_PHASE1":450,"PHASE1":452,"PHASE2":454,"PHASE3":456,"PHASE4":458,"NA":460},{"trials":451,"activeCount":9},[],{"trials":453,"activeCount":9},[],{"trials":455,"activeCount":9},[],{"trials":457,"activeCount":9},[],{"trials":459,"activeCount":9},[],{"trials":461,"activeCount":9},[462],{"nctId":463,"briefTitle":464,"status":168,"phases":465,"primaryCompletion":466,"completion":466,"start":467,"enrollment":468,"conditions":469,"interventions":471},"NCT05336825","CO2 Laser vs Lidocaine for Vestibulodynia in Premenopausal Women",[61],"2021-01-31","2019-04-01",10,[470],"Vulvodynia",[448],{"intervention":473,"totalTrials":31,"cells":474},"nicotine replacement therapy and bupropion",{"EARLY_PHASE1":475,"PHASE1":477,"PHASE2":479,"PHASE3":481,"PHASE4":483,"NA":485},{"trials":476,"activeCount":9},[],{"trials":478,"activeCount":9},[],{"trials":480,"activeCount":9},[],{"trials":482,"activeCount":9},[],{"trials":484,"activeCount":9},[],{"trials":486,"activeCount":9},[487],{"nctId":488,"briefTitle":489,"status":261,"phases":490,"completion":491,"start":492,"enrollment":493,"conditions":494,"interventions":496},"NCT00436943","Smoking Cessation Program: A Quality Improvement Trial in a Resident-Based Outpatient Clinic",[],"2008-01","2007-01",900,[495],"Smoking",[473],{"intervention":446,"totalTrials":31,"cells":498},{"EARLY_PHASE1":499,"PHASE1":501,"PHASE2":503,"PHASE3":505,"PHASE4":507,"NA":509},{"trials":500,"activeCount":9},[],{"trials":502,"activeCount":9},[],{"trials":504,"activeCount":9},[],{"trials":506,"activeCount":9},[],{"trials":508,"activeCount":9},[],{"trials":510,"activeCount":9},[511],{"nctId":437,"briefTitle":438,"status":168,"phases":512,"primaryCompletion":440,"completion":440,"start":441,"enrollment":442,"conditions":513,"interventions":514},[61],[444],[413,446]]